Comparison · NCT01131585-sae
Active Laser Photocoagulation and Ranibizumab vs Active Laser Photocoagulation and Sham Injection: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Active Laser Photocoagulation and Ranibizumab vs Active Laser Photocoagulation and Sham Injection: serious adverse events. Trial comparisons, record NCT01131585-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01131585-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.165 | 0.101 | 0.258 | wilson | |
| Risk in group 2 | 0.116 | 0.0507 | 0.245 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0484 | -0.0951 | 0.162 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.42 | 0.546 | 3.67 | log | |
| Odds ratio, group 1 over group 2 | 1.5 | 0.502 | 4.48 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Active Laser Photocoagulation and Ranibizumab than on Active Laser Photocoagulation and Sham Injection | 20.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Active Laser Photocoagulation and Ranibizumab | Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.~Ranibizumab intravitreal injection given at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment. | 14 | 85 | EG000 |
| Group 2 | Active Laser Photocoagulation and Sham Injection | Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.~Sham intravitreal injection given at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment. | 5 | 43 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy of Ranibizumab in Diabetic Macular Edema
- NCT number
- NCT01131585
- Phases
- PHASE3
- Conditions
- Visual Impairment Due to Diabetic Macular Edema
- Interventions
- Active laser photocoagulation, Sham injections, Ranibizumab 0.5 mg
- Lead sponsor
- Novartis Pharmaceuticals
- Results first posted
- 2012-08-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01131585?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01131585-sae